From our private database of 35,400+ case briefs...
In re Pfizer Inc. Shareholder Derivative Litigation
United States District Court for the Southern District of New York
722 F. Supp. 2d 453 (2010)
In 2009 the United States Department of Justice imposed a $2.3 billion fine on Pfizer, Inc., for illegally marketing Bextra and Celebrex, prescription pain relievers manufactured by Pfizer and its subsidiary Pharmacia, for off-label uses that were not approved by the Federal Drug Administration. Pfizer and its subsidiaries engaged in a pattern of off-label drug marketing and had been fined for those practices multiple times prior to 2009. Pfizer’s sales representatives promoted off-label uses to physicians and were encouraged to make false claims about the safety of these uses. Pfizer also commissioned articles published in medical journals that promoted off-label uses for certain prescription drugs and held educational programs to promote the off-label uses to physicians. Several investors (collectively, the investors) (plaintiffs) filed shareholder derivative suits against Pfizer executives and board members (collectively, the directors) (defendants) seeking recovery on behalf of Pfizer from the directors. The investors claimed that the directors were responsible for the misconduct that resulted in the fines and concluded that the directors should be held liable for the illegal drug marketing. The directors filed a motion to dismiss the case because the investors had failed to send a demand letter to the directors asking the directors to remedy the wrongdoing.
Rule of Law
Holding and Reasoning (Rakoff, J.)
What to do next…
Unlock this case brief with a free (no-commitment) trial membership of Quimbee.
You’ll be in good company: Quimbee is one of the most widely used and trusted sites for law students, serving more than 617,000 law students since 2011. Some law schools—such as Yale, Berkeley, and Northwestern—even subscribe directly to Quimbee for all their law students.Unlock this case briefRead our student testimonials
Learn more about Quimbee’s unique (and proven) approach to achieving great grades at law school.
Quimbee is a company hell-bent on one thing: helping you get an “A” in every course you take in law school, so you can graduate at the top of your class and get a high-paying law job. We’re not just a study aid for law students; we’re the study aid for law students.Learn about our approachRead more about Quimbee
Here's why 617,000 law students have relied on our case briefs:
- Written by law professors and practitioners, not other law students. 35,400 briefs, keyed to 984 casebooks. Top-notch customer support.
- The right amount of information, includes the facts, issues, rule of law, holding and reasoning, and any concurrences and dissents.
- Access in your classes, works on your mobile and tablet. Massive library of related video lessons and high quality multiple-choice questions.
- Easy to use, uniform format for every case brief. Written in plain English, not in legalese. Our briefs summarize and simplify; they don’t just repeat the court’s language.